CCKBR and familial pancreatic carcinoma: Since our polyplex NP was designed to selectively target cells that over-express the CCK-B receptor (like PanINs and pancreatic cancer), this form of precision medicine decreases the likelihood of uptake and off-target toxicity in other organs that lack this receptor.